Washington, D.C. 20549





Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): August 6, 2014



(Exact name of registrant as specified in its charter)


Nevada   333-184881   45-5401931
(State or other jurisdiction of   (Commission File Number)   (IRS Employer
incorporation)       Identification No.)


546 Fifth Avenue, 14rd Floor

New York, NY

(Address of principal executive offices)   (Zip Code)


Registrant’s telephone number, including area code (212) 702-7163


Camp Nine, Inc.
(Former name or former address, if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))






Item 7.01. Regulation FD Disclosure.


On July 8, 2014, Relmada Therapeutics, Inc. (the “Company”) changed its name from Camp Nine, Inc. to Relmada Therapeutics, Inc (the “Name Change”). This became effective in accordance with Certificate of Amendment to Articles of Incorporation filed with the State of Nevada. In connection with the Financial Industry Regulatory Authority's ("FINRA") Rule 6490 and Rule 10b-17 of the United States Securities Exchange Act of 1934, as amended, on July 9, 2014, the Company submitted an issuer company-related action notification form to FINRA notifying FINRA of the Name Change. On August 5, 2014, FINRA notified the Registrant that the Name Change had been approved with an effective date of August 6, 2014.


On August 6, 2014, in connection with the Name Change, the Company issued the press release attached hereto as Exhibit 99.1 announcing the Name Change. In accordance with General Instruction B.2 of Form 8-K, the information set forth herein and in the press release is deemed to be "furnished" and shall not be deemed to be "filed" for purposes of the Securities Exchange Act of 1934, as amended. The information set forth in Item 7.01 of this Current Report on Form 8-K shall not be deemed an admission as to the materiality of any information in this Current Report on Form 8-K that is required to be disclosed solely to satisfy the requirements of Regulation FD.


Item 8.01 Other Events


In connection with the Name Change, the Company also requested and received an updated stock trading ticker symbol, "RLMD", which was assigned and deemed effective by FINRA as of August 6, 2014, with respect to the Company's shares of common stock. In addition, as a result of the Name Change, the Company's new CUSIP number is " 75955J105".


Item 9.01 Financial Statements and Exhibits.


(d) Exhibits.


Exhibit No.    Description
99.1    Press Release, dated August 6, 2014.






Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Dated:  August 7, 2014 RELMADA THERAPEUTICS, INC.
  By: /s/ Sergio Traversa

Name: Sergio Traversa

Title:   Chief Executive Officer